Protealis Secures 1.2m EUR VLAIO grants to Advance Local High-Performing Legume Crop Innovations in Northern Europe

Ghent (Belgium), 6 November 2024 – Protealis, a leading seed and seed technologies developer for high-performing legume crops in Europe, today announces it has received EUR 1.2 million in funding from VLAIO, the Flemish Agency for Innovation & Entrepreneurship. This grant will support two ground-breaking projects - UpCoat and Tast-Y- aimed at accelerating the development and commercialization of local, high-value legume seeds, tailored for European farmers as well as the rapidly evolving local plant protein food market in Europe.

Benjamin Laga, CEO of Protealis, commented: “This support from VLAIO is invaluable in driving our commitment to local, sustainable crop solutions for Europe. UpCoat and Tast-Y will bring transformative innovations that benefit both farmers ánd the food industry, while helping Europe achieve greater self-sufficiency in protein sources.”

The UpCoat project focuses on scaling Protealis’ breakthrough soy seed coating technology. This technology coats live Nitrogen-fixing bacteria on soybean seeds. Legume crops like soy require what is called ‘inoculation’ or coating of the seeds with Bradyrhizobium bacteria strains that remain biologically active even in this temperate Western European climate. The soybean plants need these bacteria to effectively extract nitrogen from the air and fix them in the root nodules, which stimulates growth and increases yield and protein content without the need for synthetic nitrogen fertilizers. Already supported by previous VLAIO grants due to its highly innovative nature, the Protealis seed coating technology differentiates through its high user-friendliness for the farmer: it will be delivered as a ‘ready-to-sow’, avoiding the need to add the inoculant manually onto the seeds. Such manual inoculation causes uneven application, reduced viability of the bacteria, and shortened product shelf life - all reducing the efficiency of the seed coating and ultimately, yield. The UpCoat project will now pave the way for accelerated market introduction, and support Protealis’ offering of total legume crop solutions for European agriculture.

The second project, Tast-Y, seeks to advance seed quality in soybean and pea to better meet consumer preferences and processing requirements in the plant-based food sector. By improving these seeds for human consumption, Tast-Y aims to reduce anti-nutritional factors (ANFs)—compounds that, while naturally evolved as a plant defence, can interfere with nutrient absorption and cause digestive discomfort. While the benefits of legumes are widely promoted, information on ANFs and how to reduce these, for example through longer soaking or cooking time, is less commonly discussed. Additionally, this project also emphasizes enhancements in taste, health benefits such as high protein content, and supports more energy-efficient processing. These improvements will allow to create legume varieties optimized for food-grade applications, while aligning with the European shift towards the use of more plant protein sources. ​

​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ *** END ***

 

More information: ​
Renate Degrave
Head of Communications and Marketing Protealis
renate.degrave@protealis.com | +32 471 53 60 64

 

About Protealis

Protealis develops superior plant protein seeds and seed technologies, optimized for the European soil and climate. Being at the forefront of sustainable agriculture, Protealis aims to empower European farmers with sustainable and resilient alternatives to traditional protein sources by developing legume seed solutions with enhanced crop yield and protein levels, while at the same time minimizing the ecological footprint. By addressing the growing demand for more plant-based protein sources, the company is committed to contribute to more sustainable food systems. Today, Protealis is a commercial-stage company with six early maturity soy varieties on the market and is headquartered in the biotechnology cluster in Ghent, Belgium. More info on www.protealis.com, LinkedIn or facebook.

 

Data protection is important to us. You are receiving this publication on the legal basis of Article 6 para 1 lit. f GDPR ("legitimate interest"). However, if you do not wish to receive further information about Protealis, email us at info@protealis.com and we will no longer process your details for this purpose. You can also find further details in our privacy statement on www.protealis.com.

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Protealis’ (‘the Company’) or, as appropriate, the Company directors' or managements' current expectations and projections concerning future events such as the Company's results of operations, financial condition, liquidity, performance, prospects, growth, strategies and the industry in which the Company operates. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

 

.

 

 

 

Get updates in your mailbox

By clicking "Subscribe" I confirm I have read and agree to the Privacy Policy.

About VIB

VIB is a leading life sciences research institute based in Belgium, renowned for its work in medical sciences, plant biology, microbiology, artificial intelligence and biotechnology. VIB's mission is to push the boundaries of scientific discovery, transform it into disruptive biotech innovations and support the growth of the life sciences ecosystem in Flanders (Belgium). VIB is a partnership with Ghent University, Hasselt University, KU Leuven, University of Antwerp, and Vrije Universiteit Brussel.

VIB drives the translation of research discoveries into innovative products and technologies for patients, consumers and society. It does so by launching new spin-offs, licensing intellectual property to companies, engaging in dynamic partnerships and fostering talent development. VIB has created 39 spin-offs in the healthcare and agrifood sectors, attracting over €1.8 billion in equity investment and has partnered intensely with industry, generating over €350 million in income. VIB’s research has led to dozens of innovative products brought to market for medical, agriculture, and food applications, with many more in development. Seven of its spin-off companies have reached the clinical stage.

Learn more at www.vib.be.

Contact